Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint Inhibitor
Status:
Recruiting
Trial end date:
2023-06-15
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate response and survival of treatment with the combination of
pembrolizumab and ramucirumab in patients with progressive metastatic TCC after immune
checkpoint inhibitor treatment.